Q-omics provides the consensus-scored CCDC149 profile across patient tissues and cancer cell-line models. CCDC149 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CCDC149 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, CCDC149 RNA expression shows 18,990 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where CCDC149 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC149 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC149 survival associations across molecular data types. CCDC149 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC149 RNA expression–survival associations across cancer types. High CCDC149 expression shows unfavorable associations in LUSC and LIHC, but favorable associations in KIRC, HNSC, PAAD and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CCDC149 RNA expression.
This table summarizes CCDC149 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for CCDC149. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC149 shows lower tumor expression in THCA, KICH, UCEC, BLCA and LUSC and higher tumor expression in LIHC. The THCA box plot shows higher CCDC149 RNA expression in normal versus tumor tissue (log2 FC = −0.948, t-test p < 0.001).
This table shows molecular features associated with CCDC149 in patient tissues and cancer cell lines. In patient samples, CCDC149 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC149 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
